Acute Myeloid Leukemia | CHOP Research Institute

Acute Myeloid Leukemia

This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’).

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).

This study involves taking a study drug called venetoclax with or without standard of care chemotherapy.

Published on
Oct 30, 2023
Three researchers at CHOP received Doris Duke Foundation awards.
Published on
Sep 8, 2023
Sarah K. Tasian, MD, received a $1 million grant to further her research into a novel immunotherapy for high-risk pediatric leukemias.
Published on
Jul 7, 2023
See highlights from the Third Annual Lymphatic Disorder Conference and Cellicon Valley ’23, and more in this week’s research news roundup.
Published on
Jun 22, 2023
Wei Tong, PhD, and colleagues found a protein interaction that appears to be a driver of hematologic malignancies.
Published on
Dec 9, 2022
This week's news roundup features an outstanding science award, Highly Cited Researchers, and STAT Wunderkinds, along with new research about cancer risk with birth defects, epilepsy, and acute myeloid leukemia.
Published on
Sep 19, 2022
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).